<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="systematic-review" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Front Vet Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2864</journal-id><journal-id journal-id-type="pmc-domain">fvets</journal-id><journal-id journal-id-type="publisher-id">Front. Vet. Sci.</journal-id><journal-title-group><journal-title>Frontiers in Veterinary Science</journal-title></journal-title-group><issn pub-type="epub">2297-1769</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9478790</article-id><article-id pub-id-type="pmcid-ver">PMC9478790.1</article-id><article-id pub-id-type="pmcaid">9478790</article-id><article-id pub-id-type="pmcaiid">9478790</article-id><article-id pub-id-type="pmid">36118342</article-id><article-id pub-id-type="doi">10.3389/fvets.2022.903890</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Veterinary Science</subject><subj-group><subject>Systematic Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Evaluation of immune responses to <italic toggle="yes">Brucella</italic> vaccines in mouse models: A systematic review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Darbandi</surname><given-names initials="A">Atieh</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alamdary</surname><given-names initials="SZ">Shabnam Zeighamy</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Koupaei</surname><given-names initials="M">Maryam</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ghanavati</surname><given-names initials="R">Roya</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Heidary</surname><given-names initials="M">Mohsen</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="c002" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/580992/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Talebi</surname><given-names initials="M">Malihe</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Microbiology, School of Medicine, Iran University of Medical Sciences</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Microbiology and Immunology, School of Medicine, Kashan University of Medical Sciences</institution>, <addr-line>Kashan</addr-line>, <country>Iran</country></aff><aff id="aff4"><sup>4</sup><institution>Behbahan Faculty of Medical Sciences</institution>, <addr-line>Behbahan</addr-line>, <country>Iran</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences</institution>, <addr-line>Sabzevar</addr-line>, <country>Iran</country></aff><aff id="aff6"><sup>6</sup><institution>Cellular and Molecular Research Center, Sabzevar University of Medical Sciences</institution>, <addr-line>Sabzevar</addr-line>, <country>Iran</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Changyong Cheng, Zhejiang A&amp;F University, China</p></fn><fn fn-type="edited-by"><p>Reviewed by: Yusuf Abba, University of Maiduguri, Nigeria; Sara Savic, Scientific Veterinary Institute Novi Sad, Serbia</p></fn><corresp id="c001">*Correspondence: Malihe Talebi <email>talebi_25@yahoo.com</email></corresp><corresp id="c002">Mohsen Heidary <email>mohsenheidary40@gmail.com</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Veterinary Infectious Diseases, a section of the journal Frontiers in Veterinary Science</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>9</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">400313</issue-id><elocation-id>903890</elocation-id><history><date date-type="received"><day>21</day><month>4</month><year>2022</year></date><date date-type="accepted"><day>08</day><month>8</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>17</day><month>09</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-21 19:25:56.063"><day>21</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2022 Darbandi, Alamdary, Koupaei, Ghanavati, Heidary and Talebi.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Darbandi, Alamdary, Koupaei, Ghanavati, Heidary and Talebi</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fvets-09-903890.pdf"/><abstract><sec><title>Introduction</title><p>Despite the accessibility of several live attenuated vaccines for animals, currently, there is no licensed vaccine for brucellosis in human populations. Available and confirmed animal vaccines may be harmful and considered inappropriate for humans. Thus, human vaccines for brucellosis are required. We aimed to evaluate the effects of <italic toggle="yes">Brucella</italic> vaccines on mouse models and discuss the potential mechanisms of these vaccines for the design of the appropriate human vaccines.</p></sec><sec><title>Materials and methods</title><p>A systematic search was carried out in Web of Science, Embase, and PubMed/Medline databases. The following MeSH terms were applied: brucellosis, vaccine, <italic toggle="yes">Brucella</italic>, and vaccination. The original manuscripts describing the <italic toggle="yes">Brucella</italic> vaccines on mouse models were included. The review articles, editorials, correspondences, case reports, case series, duplicate publications, and articles with insufficient data were excluded.</p></sec><sec><title>Results</title><p>Of the 163 full texts that were screened, 17 articles reached to inclusion criteria. Combining the results of these trials revealed a reduction in bacterial load and colonization rate of <italic toggle="yes">Brucella</italic> in the spleen, an increase in inflammatory markers, especially IFN-&#947; and IL-4, and the highest levels of antibody classes in vaccinated animals compared to animals challenged with various virulent strains of <italic toggle="yes">Brucella</italic>. The majority of studies found that different anti-<italic toggle="yes">Brucella</italic> vaccines induced a significant protective effect in animals challenged with <italic toggle="yes">Brucella</italic> strains. Additionally, mice were given the highest level of <italic toggle="yes">Brucella</italic> vaccine protection and significant clearance of <italic toggle="yes">Brucella</italic> strains when the immunization was delivered <italic toggle="yes">via</italic> the IP (intraperitoneal) or IP-IN (intranasal) routes.</p></sec><sec><title>Conclusion</title><p>Brucella is responsible for half-million new cases globally annually, and the lack of a proper human vaccine poses the risk of brucellosis. A variety of vaccines are used to prevent brucellosis. Subunit vaccines and recombinant human vaccines have higher safety and protective properties. Although vaccination helps brucellosis control, it does not eradicate the disease. Thus, we recommend the following strategies. (a) establishment of a registration system; (b) close monitoring of slaughterhouses, markets, and herds; (c) training veterinarians; (d) legal protection of the consequences of non-compliance with preventive measures.</p></sec></abstract><kwd-group><kwd>brucellosis</kwd><kwd>vaccine</kwd><kwd><italic toggle="yes">Brucella</italic></kwd><kwd>vaccination</kwd><kwd>mouse</kwd></kwd-group><counts><fig-count count="1"/><table-count count="3"/><equation-count count="0"/><ref-count count="55"/><page-count count="15"/><word-count count="7972"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Brucellosis is one the most prevalent zoonotic infectious diseases in the world, which affects abortion and infertility in domestic animals and is characterized with undulant fever and severe debilitating symptoms in humans. <italic toggle="yes">Brucella</italic> is considered as a class B bioterrorism due to its propensity for airborne transmission, its highly infectious nature, as well as its delayed diagnosis in favor of acquiring a chronic stage (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). It also causes serious economic damage to the livestock industry due to offspring mortality, reduced milk production, and infertility. Evidence suggests that human brucellosis is associated with the disease persistence in livestock, emphasizing the importance of livestock vaccination as a controlling factor for brucellosis in animals and humans. Although S19, RB51, and REV-1, as currently licensed livestock vaccines, have been successfully used with 70% efficacy, they are inadequate for human use due to residual virulence that could result in the development of tmye disease (<xref rid="B3" ref-type="bibr">3</xref>). In the absence of a suitable human <italic toggle="yes">Brucella</italic> vaccine, animal vaccination is crucial not only to protect animal health but also to prevent zoonotic transmission. However, they have several disadvantages as follows: (i) they are still virulent for human, (ii) they are responsible for abortion when administered to pregnant animals, (iii) differentiate between infected and vaccinated animals is very difficult because they also induce a persistent serological response, and (iv) they are relatively unstable. Nevertheless, vaccination remains as the most successful and economic method for preventing and controlling brucellosis (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). In order to avoid these drawbacks, alternative vaccination approaches or new generation of vaccines are needed. In developing countries, vaccination could be the only feasible strategy for brucellosis control programs. In fact, in areas with high prevalence or recurrence of brucellosis, vaccination of all animals over a short period of time is an effective management strategy. However, these vaccines have some drawbacks that make their use challenging; for example, S19 and Rev-1 could induce abortion in pregnant animals, and retention of their lipopolysaccharide (LPS) in vaccinated animals makes it difficult to differentiate vaccinated from naturally infected animals using serological methods (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). These livestock vaccines are ~70% efficacious and are not considered safe to humans. At present, no vaccine is available for human use. Firstly, the residual virulence of live vaccines in humans and the abortifacient potential of smooth vaccines in pregnant animals make their use challenging. Also, the inability of these vaccines to induce an efficacious cross-protection against different <italic toggle="yes">Brucella</italic> species, affecting different animal species, limits their applicability (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). Additionally, when S19 or RB51 vaccines are used in animals, the interference of vaccine-induced antibody response with conventional serological tests also creates problems during surveillance programs. Secondly, the production of these vaccines is complicated, and the development of an efficacious vaccine for brucellosis has been a challenge for scientists for many years. Therefore, the main focus of this review was to collect and compare different parameters affected by anti-<italic toggle="yes">Brucella</italic> vaccination in animal models and to investigate whether vaccination agents used in animal models could also be effective for humans.</p></sec><sec sec-type="materials and methods" id="s2"><title>Materials and methods</title><p>The current study was carried out following the &#8220;Preferred Reporting Items for Systematic Reviews and Meta-Analyses&#8221; (PRISMA) statement (<xref rid="B9" ref-type="bibr">9</xref>).</p><sec><title>Search strategies</title><p>A comprehensive search was performed on the Web of Science, Embase, and PubMed/Medline databases to collect potentially relevant articles published from January 1, 2011 to March 25, 2021. The search was focused only on original articles published in English. The following keywords were used: &#8220;brucellosis,&#8221; &#8220;vaccine,&#8221; &#8220;vaccination,&#8221; &#8220;<italic toggle="yes">Brucella</italic>,&#8221; &#8220;<italic toggle="yes">Brucella suis</italic>,&#8221; &#8220;<italic toggle="yes">Brucella melitensis</italic>,&#8221; &#8220;<italic toggle="yes">Brucella abortus</italic>,&#8221; &#8220;<italic toggle="yes">Brucella canis</italic>&#8221;.</p></sec><sec><title>Study selection</title><p>Research articles examining the <italic toggle="yes">Brucella</italic> vaccines on mouse models were included in this study. We excluded the original papers describing <italic toggle="yes">in-vitro</italic> or <italic toggle="yes">ex-vivo</italic> evaluations. Moreover, the review articles, editorials, correspondences, case reports, case series, duplicate publications, and articles with insufficient data were excluded. Selected studies were screened in two steps for eligibility. First, the title and abstract screening process was performed to identify articles possibly relevant to the research domain, then the full-text of those articles that seemed to meet the inclusion criteria was retrieved. Two authors independently checked the inclusion criteria in potentially relevant articles, and discrepancies between the authors were resolved by consensus discussion. Selected articles were then evaluated qualitatively.</p></sec><sec><title>Quality assessment</title><p>Quality assessment was carried out on selected studies using the critical appraisal checklist provided by the Joanna Briggs Institute (JBI) (<xref rid="B10" ref-type="bibr">10</xref>). Eventually, eligible articles with high quality were selected and included in this research.</p></sec><sec><title>Data extraction</title><p>The articles included in this research were subjected into data extraction process. The extracted data from the high-quality eligible articles were as follows: first author's name, published time, country, sample group, control measures, name of vaccine, type of vaccine, injection route, booster, adjutant and challenge outcomes.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>Initially, 2110 references were found in the following databases: PubMed (<italic toggle="yes">n</italic> = 739), Web of Science (<italic toggle="yes">n</italic> = 782), and Embase (<italic toggle="yes">n</italic> = 589). A summary of the search strategy and study selection process is shown in <xref rid="F1" ref-type="fig">Figure 1</xref>. By reviewing titles and abstracts, 1,118 articles were excluded for different reasons (duplicate studies as well as titles and abstracts irrelevant to the topic of this review), and 163 articles were retained for detailed full-text evaluation. Among which 146 articles were also excluded as irrelevant. Finally, 17 articles describing different attenuated and recombinant vaccines against brucellosis in animal models were selected and used in this research for further analysis. Among the 17 articles reviewed, two studies used live attenuated <italic toggle="yes">B. melitensis</italic> vaccines (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B11" ref-type="bibr">11</xref>), and two studies evaluated the effects of two new vaccine formulations against <italic toggle="yes">B. melitensis</italic> 16M, including live <italic toggle="yes">Escherichia coli</italic> expressing <italic toggle="yes">Brucella</italic> P39 protein combined with CpG oligodeoxynucleotides as well as recombinant invasive <italic toggle="yes">E. coli</italic> expressing <italic toggle="yes">B. melitensis</italic> outer membrane proteins (Omp31 or Omp16) and periplasmic protein BP26 (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Also, two studies investigated the effects of <italic toggle="yes">Salmonella Typhimurium</italic> (ST) vector vaccine and attenuated <italic toggle="yes">Salmonella</italic> strains secreting <italic toggle="yes">Brucella</italic> antigens (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). The characteristics of the 17 studies included in this research are shown in <xref rid="T1" ref-type="table">Table 1</xref>.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>Flow diagram detailing the literature search and study selection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fvets-09-903890-g0001.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Characteristics of the included studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">
<bold>References</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Country</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Publication Year</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Sample group (wks. old)</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Vaccine</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Period (days)</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Vaccine dose CFU/ml (volume &#956;l)</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Vaccine candidate</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Challenge dose (CFU/mice; volume &#956;l)</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Control measures</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Injection route</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Booster</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Adjutant</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Outcome</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Alizadeh et al. (<xref rid="B22" ref-type="bibr">22</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Iran</td><td valign="top" align="left" rowspan="1" colspan="1">2019</td><td valign="top" align="left" rowspan="1" colspan="1">Female BALB/c mice (6&#8211;7)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">B. abortus</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">44 days (28:imz/14:chg)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">rOMP 16 kDa</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544 or <italic toggle="yes">B. melitensis</italic><break/> 16M (10<sup>5</sup>;-)</td><td valign="top" align="left" rowspan="1" colspan="1">PBS</td><td valign="top" align="left" rowspan="1" colspan="1">SC</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">rOmp16 is able to elicit efficient protective immune responses in animal hosts, increase IFN-&#947; and IL-4 levels, and increase total serum IgG level along with remarkable IgG1 and IgG2a responses.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Al-Mariri et al. (<xref rid="B13" ref-type="bibr">13</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Syria</td><td valign="top" align="left" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">SPF female BALB/c mice (5)</td><td valign="top" align="left" rowspan="1" colspan="1">Live <italic toggle="yes">E. coli</italic> expressing <italic toggle="yes">Brucella</italic> P39</td><td valign="top" align="left" rowspan="1" colspan="1">Group 1: 68 (56:imz/12 chg) Group 2: 96 (84:imz/12 chg)</td><td valign="top" align="left" rowspan="1" colspan="1">5 &#215; 10<sup>6</sup></td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">p39</italic> gene of <italic toggle="yes">B. melitensis</italic></td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic><break/> 16M (5 &#215; 10<sup>4</sup>;-)</td><td valign="top" align="left" rowspan="1" colspan="1">PBS</td><td valign="top" align="left" rowspan="1" colspan="1">IP</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Yes (CpG oligonu<break/>cleotides)</td><td valign="top" align="left" rowspan="1" colspan="1">This vaccine significantly reduced the number of <italic toggle="yes">B. melitensis</italic> 16M bacterial strains in mice spleens post-challenge infection, but this reduction was less than that induced by the Rev.1 vaccine.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Arenas-Gamboa et al. (<xref rid="B25" ref-type="bibr">25</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Female B6.129s2-<italic toggle="yes">Irf1tm1<break/>Mak</italic>/J(6-8) mice</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M<break/>
<italic toggle="yes">B. melitensis</italic> 16M_vjbR<break/>
<italic toggle="yes">B. abortus</italic> S19</td><td valign="top" align="left" rowspan="1" colspan="1">67 (60:imz/7:chg)</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#215; 10<sup>6</sup></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M biovar 1 (5 &#215; 10<sup>6</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">PBS</td><td valign="top" align="left" rowspan="1" colspan="1">IP</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Safety and protective efficacy of the vjbR mutant in an immunocompromised mouse model</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> S19_vjbR<break/>
<italic toggle="yes">B. abortus</italic> 2308</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Curina et al. (<xref rid="B11" ref-type="bibr">11</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Italy</td><td valign="top" align="left" rowspan="1" colspan="1">2018</td><td valign="top" align="left" rowspan="1" colspan="1">Female BALB/c mice (4) and sheep (-)</td><td valign="top" align="left" rowspan="1" colspan="1">Live attenuated REV1</td><td valign="top" align="left" rowspan="1" colspan="1">90 day: mice 150 days: sheep</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#215; 10<sup>6</sup> (500) Mice:<break/> 1.6 &#215; 10<sup>9</sup>/0.6 &#215; 10<sup>9</sup>/0.8 &#215; 10<sup>9</sup>/3.2 &#215; 10<sup>9</sup><break/> Sheep: 1,000</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Saline = mice Physiological solution = sheep</td><td valign="top" align="left" rowspan="1" colspan="1">IP: mice<break/> SC: sheep</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">REV1 vaccine produced in bioreactor stimulated all immunocompetent cells tested, with a balanced innate and adaptive response in both sheep and mice.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Clapp et al. (<xref rid="B24" ref-type="bibr">24</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">2016</td><td valign="top" align="left" rowspan="1" colspan="1">Female BALB/c mice: CD4<sup>&#8722;/&#8722;</sup> and CD8<sup>&#8722;/&#8722;</sup> C57BL/6 mice: IFN-&#947;<sup>&#8722;/&#8722;</sup> BALB/c mice: (7&#8211;9)</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice<italic toggle="yes">:</italic> &#916;znuA <italic toggle="yes">B. melitens</italic> RB51, S19:<break/> IFN-&#947;<sup>&#8722;/&#8722;</sup> mice:<break/> &#916;znuA <italic toggle="yes">B. melitensis</italic>:<break/> CD4<sup>&#8722;/&#8722;</sup> and CD8<sup>&#8722;/&#8722;</sup><break/> mice: &#916;znuA <italic toggle="yes">B. melitensis</italic>, Rev-1</td><td valign="top" align="left" rowspan="1" colspan="1">70 (42:imz/28:chg)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">-</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> strain 16M <italic toggle="yes">(-)</italic></td><td valign="top" align="left" rowspan="1" colspan="1">PBS</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Stimulating systemic and mucosal immune protection <italic toggle="yes">via</italic> CD8+ T cell engagement</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gonz&#225;lez-Gonz&#225;lez et al. (<xref rid="B21" ref-type="bibr">21</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Mexico</td><td valign="top" align="left" rowspan="1" colspan="1">2014</td><td valign="top" align="left" rowspan="1" colspan="1">Female BALB/c mice (6&#8211;8)</td><td valign="top" align="left" rowspan="1" colspan="1">RB51</td><td valign="top" align="left" rowspan="1" colspan="1">77 weeks (56;imz/21:chg)</td><td valign="top" align="left" rowspan="1" colspan="1">4 &#215; 10<sup>9</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Protoxin Cry1Ac of <italic toggle="yes">B. thuringiensis</italic></td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus 2308</italic> (4 &#215; 10<sup>6</sup>;-)</td><td valign="top" align="left" rowspan="1" colspan="1">PBS</td><td valign="top" align="left" rowspan="1" colspan="1">IN</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Yes (Protoxin Cry1Ac)</td><td valign="top" align="left" rowspan="1" colspan="1">The use of Cry1Ac protein as a mucosal adjuvant <italic toggle="yes">via</italic> the intranasal route could be a promising alternative to improve the current RB51 vaccine against brucellosis, with a more intense Th1-type response.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gupta et al. (<xref rid="B12" ref-type="bibr">12</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">India</td><td valign="top" align="left" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c female mice (4&#8211;6)</td><td valign="top" align="left" rowspan="1" colspan="1">Invasive <italic toggle="yes">E. coli</italic> (DH5&#945;)</td><td valign="top" align="left" rowspan="1" colspan="1">63</td><td valign="top" align="left" rowspan="1" colspan="1">2 &#215; 10<sup>7</sup> (200)</td><td valign="top" align="left" rowspan="1" colspan="1">Omp31 or Omp16 or periplasmic protein BP26</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M (2 &#215; 10<sup>4</sup>;-)</td><td valign="top" align="left" rowspan="1" colspan="1">Saline</td><td valign="top" align="left" rowspan="1" colspan="1">IP</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Invasive <italic toggle="yes">E. coli</italic> vaccines induce a cellular immune response and protect mice against infectious <italic toggle="yes">B. melitensis</italic> 16M challenge.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Jacob and Curtiss (<xref rid="B17" ref-type="bibr">17</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">2021</td><td valign="top" align="left" rowspan="1" colspan="1">SPF female BALB/c (8)</td><td valign="top" align="left" rowspan="1" colspan="1">Attenuated S19</td><td valign="top" align="left" rowspan="1" colspan="1">56</td><td valign="top" align="left" rowspan="1" colspan="1">7.3 &#215; 10<sup>6</sup> :IP (100)<break/> 8.5 &#215; 10<sup>6</sup>:SC<break/> (100)<break/> 5.1 &#215; 10<sup>7</sup> :IN (25)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">-</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">IP<break/> SC<break/> IN</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">S19 could be used safely and economically under BSL2 containment.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Jain et al. (<xref rid="B26" ref-type="bibr">26</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">India</td><td valign="top" align="left" rowspan="1" colspan="1">2015</td><td valign="top" align="left" rowspan="1" colspan="1">Female Swiss albino mice (4&#8211;5</td><td valign="top" align="left" rowspan="1" colspan="1">S19</td><td valign="top" align="left" rowspan="1" colspan="1">45 days (30:imz/<break/>15:chg)</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#215; 10<sup>5</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Aluminum hydroxide gel Adjuvanted phage lysate of S19</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544 (2 &#215; 10<sup>5</sup>;-)</td><td valign="top" align="left" rowspan="1" colspan="1">BSS</td><td valign="top" align="left" rowspan="1" colspan="1">SC</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Yes (PL-Plain or AD-Alum adjuvanted lysate)</td><td valign="top" align="left" rowspan="1" colspan="1">Adjuvanted phage lysate exhibited the highest protective potency which was greater than that induced by standard S19 vaccine.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Jain-Gupta et al. (<xref rid="B20" ref-type="bibr">20</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Female BALB/c mice (6&#8211;8)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M</td><td valign="top" align="left" rowspan="1" colspan="1">45 (30:imz/<break/>15:chg)</td><td valign="top" align="left" rowspan="1" colspan="1">5 &#956;g</td><td valign="top" align="left" rowspan="1" colspan="1">OMP</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic><break/> (2 &#215; 10<sup>4</sup>;-)</td><td valign="top" align="left" rowspan="1" colspan="1">Saline</td><td valign="top" align="left" rowspan="1" colspan="1">IP</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Yes (Pluronic P85)</td><td valign="top" align="left" rowspan="1" colspan="1">P85 enhanced the <italic toggle="yes">in vitro</italic> secretion of TNF-&#945; by macrophages, enhanced the protection against <italic toggle="yes">B. melitensis</italic> challenge, and increased total IgG antibody production, but did not increase IFN-&#947; or IL-4 cytokine levels.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lalsiamthara et al. (<xref rid="B15" ref-type="bibr">15</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Korea</td><td valign="top" align="left" rowspan="1" colspan="1">2018</td><td valign="top" align="left" rowspan="1" colspan="1">SPF female BALB/c mice (4)</td><td valign="top" align="left" rowspan="1" colspan="1">Rough attenuated ST strain JOL1800 (JOL1878, JOL1879, JOL1880, and JOL1881) + LPS <italic toggle="yes">Brucella</italic></td><td valign="top" align="left" rowspan="1" colspan="1">45 (30:imz/<break/>15:chg)</td><td valign="top" align="left" rowspan="1" colspan="1">2&#8211;8 &#215; 10<sup>7</sup><break/> LPS: 5 &#956;g</td><td valign="top" align="left" rowspan="1" colspan="1">rB BLS Omp19 SOD PRAC SbA</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B</italic>. <italic toggle="yes">abortus</italic><break/> 544 (2 &#215; 10<sup>5</sup>; 200)</td><td valign="top" align="left" rowspan="1" colspan="1">PBS</td><td valign="top" align="left" rowspan="1" colspan="1">IP<break/> IM<break/> SC<break/> OR</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">ST successfully induced an antigen-specific immune response. More effective protection was observed by inoculation <italic toggle="yes">via</italic> the IP and IM routes.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Minhas et al. (<xref rid="B19" ref-type="bibr">19</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">India</td><td valign="top" align="left" rowspan="1" colspan="1">2019</td><td valign="top" align="left" rowspan="1" colspan="1">Male Swiss albino(8) mice</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant <italic toggle="yes">Brucella</italic> Omp22</td><td valign="top" align="left" rowspan="1" colspan="1">31</td><td valign="top" align="left" rowspan="1" colspan="1">50 &#956;g: recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">rOmp22</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">rOmp22 alone</td><td valign="top" align="left" rowspan="1" colspan="1">SC</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">FCA, FIA (control); rDnaJ9 (experiment)</td><td valign="top" align="left" rowspan="1" colspan="1">rDnaJ from <italic toggle="yes">Brucella</italic> spp. could have immuno-modulatory properties and may stimulate both humoral as well as CMI arms of the immune system.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mansour (<xref rid="B23" ref-type="bibr">23</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Saudi Arabia</td><td valign="top" align="left" rowspan="1" colspan="1">2017</td><td valign="top" align="left" rowspan="1" colspan="1">Female Bulb/C mice (7&#8211;8)</td><td valign="top" align="left" rowspan="1" colspan="1">RB51</td><td valign="top" align="left" rowspan="1" colspan="1">70</td><td valign="top" align="left" rowspan="1" colspan="1">5 &#215; 10<sup>8</sup></td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic><break/> bivar 3 (2 &#215; 10<sup>4</sup>; 2,000)</td><td valign="top" align="left" rowspan="1" colspan="1">RB51</td><td valign="top" align="left" rowspan="1" colspan="1">IP</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">levamisole</td><td valign="top" align="left" rowspan="1" colspan="1">Levamisole given 7 days or 0 and 7 days post-vaccination enhanced humoral and cell-mediated immune responses to RB51 strain (cytotoxic T cells).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Senevirathne et al. (<xref rid="B14" ref-type="bibr">14</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Korea</td><td valign="top" align="left" rowspan="1" colspan="1">2019</td><td valign="top" align="left" rowspan="1" colspan="1">SPF female BALB/c mic</td><td valign="top" align="left" rowspan="1" colspan="1">Attenuated ST strain<break/> JOL1874<break/> JOL1875<break/> JOL1876<break/> JOL1877</td><td valign="top" align="left" rowspan="1" colspan="1">45 (30:imz/<break/>14:chg)</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#215; 10<sup>7</sup> (100)</td><td valign="top" align="left" rowspan="1" colspan="1">SodC Omp19 BLS PrpA</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544 (2 &#215; 10<sup>5</sup>;-)</td><td valign="top" align="left" rowspan="1" colspan="1">PBS</td><td valign="top" align="left" rowspan="1" colspan="1">IP</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Efficiently conferring a dual protection against both brucellosis and salmonellosis in immunized mice</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Surendran et al. (<xref rid="B16" ref-type="bibr">16</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">2011</td><td valign="top" align="left" rowspan="1" colspan="1">Female BALB/c mice (6&#8211;8)</td><td valign="top" align="left" rowspan="1" colspan="1">Live attenuated<break/> RB51<break/> Live attenuated Smooth S9<break/> Rough RB51<break/> RB51SOD<break/> RB51WboA<break/> Smooth <italic toggle="yes">B. abortus</italic> 2308</td><td valign="top" align="left" rowspan="1" colspan="1">44 or 85 (42:imz/14 or 41:chg)</td><td valign="top" align="left" rowspan="1" colspan="1">4 &#215; 109<break/> 4 &#215; 108</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Smooth <italic toggle="yes">B. abortus</italic> strain 2308<break/> (2 &#215; 10<sup>5</sup>;-)<break/> (2 &#215; 10<sup>4</sup>;-)</td><td valign="top" align="left" rowspan="1" colspan="1">PBS</td><td valign="top" align="left" rowspan="1" colspan="1">IN<break/> IP<break/> IM</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">IN administration of <italic toggle="yes">B. abortus</italic> vaccine strain 19 induced significant pulmonary clearance of <italic toggle="yes">B. abortus</italic> pathogenic strain 2308, but not rough RB51, RB51SOD, and RB51WboA vaccine strains. Neither strain RB51SOD nor strain RB51WboA induced significant improvement in pathogen clearance</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">compared to strain RB51 upon IN vaccination.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Zhu et al. (<xref rid="B18" ref-type="bibr">18</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">China</td><td valign="top" align="left" rowspan="1" colspan="1">2016</td><td valign="top" align="left" rowspan="1" colspan="1">Female BALB/c mice (6) Female guinea pigs (300&#8211;400 g)</td><td valign="top" align="left" rowspan="1" colspan="1">Live attenuated S2</td><td valign="top" align="left" rowspan="1" colspan="1">86 (56:imz/30 chg)</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#215; 10<sup>5</sup><break/> (200)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis M</italic> 28<break/>
<italic toggle="yes">B. abortus</italic>2308<break/>
<italic toggle="yes">B. suis</italic> S1330<break/> (1 &#215; 10<sup>5</sup>; 200)</td><td valign="top" align="left" rowspan="1" colspan="1">Saline</td><td valign="top" align="left" rowspan="1" colspan="1">SC</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">S2 vaccine stimulates good humoral and cellular immunity and protects animals against infection by heterologous, virulent <italic toggle="yes">Brucella</italic> species.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Zhu et al. (<xref rid="B27" ref-type="bibr">27</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">USA</td><td valign="top" align="left" rowspan="1" colspan="1">2011</td><td valign="top" align="left" rowspan="1" colspan="1">Female BALB/c mice (4&#8211;5)</td><td valign="top" align="left" rowspan="1" colspan="1">Live attenuated RB51<break/> RB51SOD</td><td valign="top" align="left" rowspan="1" colspan="1">42&#8211;49</td><td valign="top" align="left" rowspan="1" colspan="1">4 &#215; 10<sup>8</sup> cells</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Saline</td><td valign="top" align="left" rowspan="1" colspan="1">IP</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Higher cytotoxic T lymphocyte activity of RB51SOD rather than its parent strain RB51 due to the overexpression of Cu/Zn SOD and its release into extracellular area</td></tr></tbody></table><table-wrap-foot><p>Imz, immunization; chg, challenge; wks old, weeks old; SPF, specific pathogen free; rB, conserved Brucella antigens; BLS, Viz lumazine synthase; PRASbA, proline racemase subunit A; Omp19, outer membrane protein-19; SOD, Cu-Zn superoxide dismutase; IP, intraperitoneal; IM, intramuscular; SC, subcutaneous; IN, intranasal; OR, oral; NA, nasal; ST, Salmonella Typhimurium; PBS, phosphate buffered saline; BSS, buffered Brucella saline; rDnaJ, Brucella-specific recombinant HSP40.</p></table-wrap-foot></table-wrap><p>Out of the 17 studies reviewed in this research, three studies (<xref rid="B15" ref-type="bibr">15</xref>&#8211;<xref rid="B17" ref-type="bibr">17</xref>) evaluated the effect of immunization route on protective efficacy of different <italic toggle="yes">Brucella</italic> vaccines. Jacob and Curtiss (<xref rid="B17" ref-type="bibr">17</xref>) revealed that the mean colonization titers of <italic toggle="yes">B. abortus</italic> S19, as a challenge strain for vaccine, in the spleen were higher in the IP (intraperitoneal) and SC (subcutaneous) groups during the first 14 days post-inoculation and then slowly decreased. On day 7, the mean CFUs (number of challenge strains) in the IP and SC groups were significantly higher than in the IN (intranasal) group (<italic toggle="yes">p</italic> &lt; 0.001<sup>**</sup>). On day 14, the mean CFU was significantly higher in the IP group than in the SC group (<italic toggle="yes">p</italic> &lt; 0.001<sup>**</sup>), as well as in the SC group than in the IN group (<italic toggle="yes">p</italic> &lt; 0.001<sup>**</sup>). In the IN group, the mean CFU in the spleen was lower than in both lungs on day 7 but higher than in both lungs on day 21. Colonization titers in the spleen in the IN group were higher than in the IP and SC groups on day 28. This study showed that colonization titers in the spleen in the IP and SC groups peaked in the first 14 days of the experiment and then slowly decreased. In contrast, colonization titers in the IN group decreased during the first 14 days, but increased on day 21 and then slowly decreased. This may be due to that S19 bacteria probably needed more time to infect the spleen in the IN group. This study showed that S19 could infect and persist in mice tissues for at least 8 weeks after inoculation <italic toggle="yes">via</italic> the IP, SC, and IN administration routes. On the other hand, Lalsiamthara et al. (<xref rid="B15" ref-type="bibr">15</xref>) investigated the effect of immunization route on the protective efficacy of the combined LPS-<italic toggle="yes">Brucella</italic> vaccine. Their study results showed that the lowest CFU levels and the highest protection level were conferred to mice when the formulation was administered <italic toggle="yes">via</italic> the IP route. The difference between the SC/IP and IM (intramuscular) routes was not significant, but there was a significant difference between the SC and IP routes. Interestingly, immunization with the rough <italic toggle="yes">Salmonella</italic>-delivered recombinant combined LPS-<italic toggle="yes">Brucella</italic> vaccine <italic toggle="yes">via</italic> the IP or IM route produced significantly higher levels of protection compared to the commercial <italic toggle="yes">B. abortus</italic> strain RB51 vaccine <italic toggle="yes">via</italic> the IP route (<italic toggle="yes">p</italic> &#8804; 0.005). Overall, mice groups immunized <italic toggle="yes">via</italic> the oral or IP route showed the production of specific IgG antibodies. Also, Surendran et al. (<xref rid="B16" ref-type="bibr">16</xref>) observed that single-dose IN vaccination with <italic toggle="yes">B. abortus</italic> strain RB51 and RB51SOD vaccines provided no protection against IN challenge with pathogenic strain 2,308 on day 14 or 41 in the lungs, spleen, or mediastinal lymph nodes (MLN). Besides, mice receiving IN booster dose showed no significant increase in bacterial clearance from the organs tested on both day 14 and day 41 compared to controls. There was no significant difference in clearance of strain 2,308 from the organs tested between various IN doses (10<sup>7</sup>, 10<sup>8</sup>, 10<sup>9</sup> CFUs/mouse). Thus, IN vaccination had no protective efficacy. Also, none of the systemic vaccination routes induced significant clearance of strain 2,308 from the organs tested compared to PBS (phosphate buffered saline) control. Furthermore, regarding the clearance of strain 2,308 from the spleen, lungs, or MLN, there was no significant difference between different vaccination routes. Besides, no significant improvement in bacterial clearance from the lungs or MLN was obtained with IP-IN combination vaccination strategy. Only IP-IN administration of the vaccine strain RB51SOD induced significant clearance of strain 2,308 from the spleen (<italic toggle="yes">p</italic> = 0.0146). Finally, IM and ID (intradermal) systemic priming followed by IN booster provided no protection in mice against IN pathogenic strain 2,308 infection in the organs tested.</p><p>Eight out of the 17 studies (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B18" ref-type="bibr">18</xref>&#8211;<xref rid="B22" ref-type="bibr">22</xref>) investigated antibody classes' responses in experimental groups (a summary is provided in <xref rid="T2" ref-type="table">Table 2</xref>). In all the eight studies reviewed, the maximum levels of antibody classes were observed in vaccinated groups. Mansour (<xref rid="B23" ref-type="bibr">23</xref>) showed that levamisole treatment either 7 days or 0 and 7 days post-vaccination by RB51 elicited a strong immune potentiating effect, so that the mean antibody levels measured by ELISA throughout the experimental period were higher in levamisole-treated mice compared to levamisole-untreated vaccinated mice. Mice treated with levamisole simultaneously (day 0) with vaccination showed a mild elevation in antibody titer compared with vaccinated mice receiving no treatment. The highest level of delayed-type hypersensitivity (DTH) was observed in the group of mice treated with levamisole 0 and 7 days post-vaccination, followed by the group of mice treated with levamisole 7 days post-vaccination and then the group of mice treated with levamisole simultaneously with vaccination.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>The antibody responses in experimental studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">
<bold>References</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Vaccine</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>IgG total</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>IgG1</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>IgG2</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>IgM</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>sIgA</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Zhu et al. (<xref rid="B18" ref-type="bibr">18</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Live attenuated <italic toggle="yes">B. suis</italic> strain 2 (S2)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gonz&#225;lez-Gonz&#225;lez et al. (<xref rid="B21" ref-type="bibr">21</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Protoxin Cry1Ac of <italic toggle="yes">Bacillus thuringiensis</italic> with RB51 vaccine strain of <italic toggle="yes">B. abortus</italic></td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8595;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Alizadeh et al. (<xref rid="B22" ref-type="bibr">22</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Outer membrane protein of <italic toggle="yes">B. abortus</italic> (Omp16)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Jain-Gupta et al. (<xref rid="B20" ref-type="bibr">20</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Pluronic P85 as an adjuvant to enhance the efficacy of <italic toggle="yes">B. melitensis</italic> OMVs</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gupta et al. (<xref rid="B12" ref-type="bibr">12</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant inv- <italic toggle="yes">E. coli</italic> expressing Omp31 or 16 and BP26 <italic toggle="yes">B. melitensis</italic> proteins</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Minhas et al. (<xref rid="B19" ref-type="bibr">19</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant HSP40 (rDnaJ) co-immunization with <italic toggle="yes">Brucella</italic> rOmp22</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lalsiamthara et al. (<xref rid="B15" ref-type="bibr">15</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">Brucella</italic> antigens delivered by <italic toggle="yes">S. Typhimurium</italic> (ST) vector</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Senevirathne et al. (<xref rid="B14" ref-type="bibr">14</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Attenuated <italic toggle="yes">Salmonella</italic> strains secreting <italic toggle="yes">Brucella</italic> antigens SodC, Omp19, BLS, and PrpA</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593;</td></tr></tbody></table></table-wrap><p>Based on <xref rid="T3" ref-type="table">Table 3</xref>, among the reviewed articles, 10 studies (<xref rid="B12" ref-type="bibr">12</xref>&#8211;<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B18" ref-type="bibr">18</xref>&#8211;<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B24" ref-type="bibr">24</xref>) investigated some inflammatory markers (IFN-&#947;, IL-4, IL-5, IL-12, IL-17, IL-22, IL-23, TNF-&#945;) in animals immunized with anti-<italic toggle="yes">Brucella</italic> vaccines and analyzed cytokine responses to immunization.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>The cytokine responses in experimental studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">
<bold>References</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>IFN-&#947;</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>IL-4</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>IL-5</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>IL-12</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>IL-17</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>IL-22</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>IL-23</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>TNF-&#945;</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Al-Mariri et al. (<xref rid="B13" ref-type="bibr">13</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lalsiamthara et al. (<xref rid="B15" ref-type="bibr">15</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Zhu et al. (<xref rid="B18" ref-type="bibr">18</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gonz&#225;lez-Gonz&#225;lez et al. (<xref rid="B21" ref-type="bibr">21</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Alizadeh et al. (<xref rid="B22" ref-type="bibr">22</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gupta et al. (<xref rid="B12" ref-type="bibr">12</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Clapp et al. (<xref rid="B24" ref-type="bibr">24</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Jain-Gupta et al. (<xref rid="B20" ref-type="bibr">20</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Minhas et al. (<xref rid="B19" ref-type="bibr">19</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Senevirathne et al. (<xref rid="B14" ref-type="bibr">14</xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">&#8593;</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap><p>Among the 17 studies reviewed, 13 articles (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B14" ref-type="bibr">14</xref>&#8211;<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B20" ref-type="bibr">20</xref>&#8211;<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B24" ref-type="bibr">24</xref>&#8211;<xref rid="B27" ref-type="bibr">27</xref>) reported the induction of a significant protective effect in vaccinated animals challenged with different virulent strains of <italic toggle="yes">Brucella</italic>. In these studies, different anti-<italic toggle="yes">Brucella</italic> vaccines conferred significantly higher levels of protection in vaccinated mice compared to saline-vaccinated mice or control groups. Also, two studies (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B26" ref-type="bibr">26</xref>) showed a decrease in bacterial load and colonization in the spleen. Gonz&#225;lez-Gonz&#225;lez et al. (<xref rid="B21" ref-type="bibr">21</xref>) showed that co-administration of pCry1Ac (adjuvant) with RB51 conferred a significant level of protection against IN challenge with virulent strain <italic toggle="yes">B. abortus</italic> 2,308, thereby reducing the spleen colonization level by 1.0 log<sub>10</sub>, which was significantly different compared to both groups of PBS control (<italic toggle="yes">p</italic> &lt; 0.05) and RB51 alone (<italic toggle="yes">p</italic> &lt; 0.05). Besides, Jain et al. (<xref rid="B26" ref-type="bibr">26</xref>) reported that on day 15 post-challenge, all lysate (plain and alum-adsorbed)-vaccinated groups showed a significant (<italic toggle="yes">p</italic> &lt; 0.05) reduction in bacterial load or total viable counts (TVC) in the spleen [protective values (Y) from 3.47 to 1.80] compared to the unvaccinated control group (<italic toggle="yes">Y</italic> = 4.81), confirming the dose-dependent protective efficacy of phage lysate. Also, one week post-challenge (9 weeks post-vaccination), a marked decrease in splenic and hepatic bacterial loads (4-log-unit reduction) was observed in mice vaccinated with the 16M&#916;vjbR mutant or S19&#916;vjbR mutant.</p></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p><italic toggle="yes">Brucella</italic> is annually responsible for 500,000 new brucellosis cases worldwide (<xref rid="B28" ref-type="bibr">28</xref>). Due to its pathogenic nature for humans, communicability, moderate side effects, and potential for use as a bioterrorism agent, <italic toggle="yes">Brucella</italic> has been introduced by the CDC as a category B agent that should be used under level 3 biosafety (<xref rid="B17" ref-type="bibr">17</xref>). The lack of a proper human vaccine poses the risk of developing brucellosis as a bioterrorism weapon (<xref rid="B28" ref-type="bibr">28</xref>). The purpose of this systematic review was to evaluate different vaccines designed against brucellosis in mouse models and their effectiveness in order to paw the way for the design and manufacture of appropriate human vaccines.</p><p>So far, various brucellosis eradication methods have been proposed, including live vaccines such as S19 and Rev1, extensive protective coverage, appropriate diagnostic tests, continuous removal of infected livestock, and restriction of animal movement from infected to free herds (<xref rid="B29" ref-type="bibr">29</xref>). Due to the economic losses associated with common infections between humans and animals (<xref rid="B30" ref-type="bibr">30</xref>), research teams are looking for new vaccines, such as subunits vaccines (<xref rid="B31" ref-type="bibr">31</xref>), bacterial vector-based vaccines (<xref rid="B32" ref-type="bibr">32</xref>), and vaccines based on overexpression of protective homologous antigens (<xref rid="B33" ref-type="bibr">33</xref>). One of the reasons for not using new vaccines is the resistance of government regulators in some countries such as developing countries (<xref rid="B34" ref-type="bibr">34</xref>).</p><p>So far, a variety of vaccines have been used to prevent brucellosis. Common types of vaccines include smooth vaccines and rough vaccines. Other types of vaccines include vector-delivered <italic toggle="yes">Brucella</italic> vaccines, genetically engineered attenuated vaccines, and subunit vaccines. Subunit vaccines are divided into two categories, including recombinant protein- and DNA-based vaccines (<xref rid="B34" ref-type="bibr">34</xref>). Vaccination has several benefits, such as limiting <italic toggle="yes">Brucella</italic> infection, limiting shedding, disrupting animal-to-animal transmission, and reducing the spread of disease between animals and humans (<xref rid="B29" ref-type="bibr">29</xref>). If vaccination is accompanied by the removal of infected animals, it could lead to the selection of more resistant strains of the disease (<xref rid="B35" ref-type="bibr">35</xref>). Dysfunctional vaccines have some disadvantages. In fact, vaccinated animals act as a source of infection and transmit malignant <italic toggle="yes">Brucella</italic> strains (<xref rid="B36" ref-type="bibr">36</xref>). The use of low-performance <italic toggle="yes">Brucella</italic> vaccines creates a false sense of security among ranchers and health officials, and may lead them to believe that the herd is fully protected (<xref rid="B36" ref-type="bibr">36</xref>).</p><p>Subunit vaccines and recombinant human vaccines have high safety and protective properties. The formulation of subunit vaccines should be optimized (for example, a suitable adjuvant should be used). In live recombinant human vaccines, the use of a vaccine vector is important (<xref rid="B37" ref-type="bibr">37</xref>). Vaccination of livestock is the most important way to prevent brucellosis until appropriate human vaccines are discovered (<xref rid="B37" ref-type="bibr">37</xref>). So far, different vaccines have been designed for human use, but each has disadvantages that make its use challenging. For example, strain 19-BA, which is applied intradermally by scarification, provides limited protection for a relatively short period of time and requires re-immunization. Another disadvantage is the occurrence of hypersensitivity reactions. <italic toggle="yes">Brucella abortus</italic> 84-C and M-104 are used intradermally or as aerosols, which seem to be effective but could cause severe reactions if not used properly or given to sensitive people (<xref rid="B38" ref-type="bibr">38</xref>).</p><p><italic toggle="yes">Brucella</italic> DNA-based vaccines are a type of subunit vaccines that could induce humoral and cellular immune responses after repeated use (<xref rid="B39" ref-type="bibr">39</xref>). DNA vaccines are plasmids that express the gene encoding a specific antigen. Among the most common genes used are L7/L12, BLS, BCSP31, SOD Cu/Zn, Omp16, P39, and BAB1-0278. Adjuvant is not commonly used in DNA vaccines (<xref rid="B3" ref-type="bibr">3</xref>). The DNA vaccine encoding BAB1-0278 protects mice against <italic toggle="yes">B. abortus</italic> (<xref rid="B40" ref-type="bibr">40</xref>). DNA vaccines containing BAB1 0273 and/or BAB1 0278 and SOD C elicit immune responses in mice, but have low protective effect (<xref rid="B41" ref-type="bibr">41</xref>). DNA vaccines encoding p39 and/or groEL as well as other DNA-based vaccine candidates require several booster vaccinations while providing low levels of protection. Therefore, more studies are needed in this area (<xref rid="B39" ref-type="bibr">39</xref>). Two methods could be used to enhance immune responses and the efficacy of <italic toggle="yes">Brucella</italic> DNA vaccines, including the expression of several antigens in DNA vaccines (Omp16 and L7/L12), and the expression of cytokines as adjuvants (SOD with IL-18 or IL-12) (<xref rid="B3" ref-type="bibr">3</xref>). DNA vaccines has been studied more in mouse models than in other natural hosts (<xref rid="B42" ref-type="bibr">42</xref>). DNA vaccines must be injected intramuscularly, which requires large amounts of DNA. Gene guns and nanoparticles could be used to solve this problem. These methods require less DNA and increase cell uptake and DNA half-life (<xref rid="B34" ref-type="bibr">34</xref>). The advantages of using these vaccines include long-term expression, better stability, safe vaccination, and easy production (<xref rid="B34" ref-type="bibr">34</xref>). DNA vaccines are suitable for those diseases against which cellular immunity is required to defend the host. These vaccines have been used in several human studies and shown to induce weaker immune responses in humans than in mice; thus, they need to be optimized. But optimization increases pro-inflammatory reactions (<xref rid="B42" ref-type="bibr">42</xref>). Among the new optimization methods that could be used for this purpose are two innovative methods of delivery and codon optimization (<xref rid="B34" ref-type="bibr">34</xref>).</p><p>In some vaccines, CpG oligonucleotides (CpG ODN) containing unmethylated CG motifs similar to those found in bacterial DNA stimulate toll-like receptors (TLRs) in vertebrates, especially TLR9 (<xref rid="B43" ref-type="bibr">43</xref>). Stimulation of these receptors triggers innate, humoral, and cellular immune responses (<xref rid="B44" ref-type="bibr">44</xref>). CpG ODN has various effects on the immune system, such as accelerating and enhancing antigen-specific immune responses, inducing Th1 and pro-inflammatory cytokines, as well as supporting the maturation and inactivation of professional antigen presenting cells (APCs). CpG ODN is safe when administered to humans as an adjuvant and may support enhanced vaccine-specific immune responses (<xref rid="B45" ref-type="bibr">45</xref>).</p><p>Dual vaccines, which are used against two pathogens, have also been tested against brucellosis. So far, dual vaccines against <italic toggle="yes">Brucella</italic> and two pathogens of <italic toggle="yes">Helicobacter pylori</italic> (<xref rid="B46" ref-type="bibr">46</xref>) and <italic toggle="yes">E. coli</italic> O157:H7 (<xref rid="B47" ref-type="bibr">47</xref>) have been used in mice. In all of these vaccines, good efficacy and immune responses have been observed. Another uncommon vaccine is the ghost vaccine, which uses <italic toggle="yes">Brucella</italic> lysed extract to create immunity. The ghost vaccine has significant protective effects on the mouse host. Due to the beneficial effects of such vaccines, it is recommended that further studies be performed on them.</p><p>It is difficult to obtain a suitable vaccine that could elicit protective responses against inhaled <italic toggle="yes">Brucella</italic> infection (<xref rid="B48" ref-type="bibr">48</xref>). Some of the reasons for the difficulty in making this kind of vaccine could be as follows. First, tested vaccines are unable to elicit an innate and efficient immune response in the lung microenvironment. Second, live <italic toggle="yes">B. abortus</italic> vaccines suppress innate immune responses and affect DCs ability to induce protective cellular immunity. Third, the intracellular nature of <italic toggle="yes">Brucella</italic> makes the vaccine unable to induce efficient acquired immunity. After inhalation, <italic toggle="yes">B. abortus</italic> multiplies in lung epithelial cells and alveolar macrophages without eliciting a strong innate immunity. Therefore, it causes the bacteria to escape from the identification and purification mechanisms of acquired immunity (<xref rid="B48" ref-type="bibr">48</xref>). It has been shown that subcutaneous (SC) administration of Rev1 reduces the bacterial load in the spleen of <italic toggle="yes">B. melitensis</italic> 16M-infected mice, but has no effect on the bacterial load in the liver and lungs. IN administration of the Rev1 vaccine reduces <italic toggle="yes">B. melitensis</italic> 16M load in the lungs and spleen (<xref rid="B49" ref-type="bibr">49</xref>).</p><p>In some of the studies reviewed in this research, weight gain or loss in organs such as the spleen was reported. Weight gain may be due to increased inflammation because the immune system responds to the presence of <italic toggle="yes">Brucella</italic> (<xref rid="B17" ref-type="bibr">17</xref>).</p><p><italic toggle="yes">Brucella</italic> infection occurs in host cells. Thus, infected cells must kill either the bacteria or themselves. In this case, antibody-mediated immunity could be used to clear the bacteria (<xref rid="B50" ref-type="bibr">50</xref>). Once <italic toggle="yes">Brucella</italic> enters the host cell, the bacteria are killed, and the bacterial peptides are processed on the surface of the APCs. These peptides are associated with MHC I and MHC II. Peptide-MHC is detected <italic toggle="yes">via</italic> TCR (T-cell receptor). CD<inline-formula><mml:math id="M1" overflow="scroll"><mml:msubsup><mml:mrow/><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> T cells recognize peptide-MHC II, and CD<inline-formula><mml:math id="M2" overflow="scroll"><mml:msubsup><mml:mrow/><mml:mrow><mml:mn>8</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> T cells recognize peptide-MHC I (<xref rid="B50" ref-type="bibr">50</xref>).</p><p>Immunity to <italic toggle="yes">B. abortus</italic> is induced in a variety of ways, including activation of antigen-specific T cells, humoral responses, CD<inline-formula><mml:math id="M3" overflow="scroll"><mml:msubsup><mml:mrow/><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> T cells, and CD<inline-formula><mml:math id="M4" overflow="scroll"><mml:msubsup><mml:mrow/><mml:mrow><mml:mn>8</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> T cells (<xref rid="B50" ref-type="bibr">50</xref>). To activate innate immunity, pathogen-associated molecular patterns (PAMPs) are first identified by TLRs, which then activate APCs. As a result, bacterial phagocytosis is facilitated (<xref rid="B50" ref-type="bibr">50</xref>). Specific subtypes of IgG, such as IgG2a and IgG3, are produced in humans in humoral responses to intracellular brucellosis (<xref rid="B50" ref-type="bibr">50</xref>). An increase in immunoglobulin levels means that the vaccine has a protective effect. In the present study, the highest increase in antibody was related to IgG total. Primary effective immunity in mice is mediated through the production of IL-12-dependent IFN-&#947; by CD<inline-formula><mml:math id="M5" overflow="scroll"><mml:msubsup><mml:mrow/><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> T and CD<inline-formula><mml:math id="M6" overflow="scroll"><mml:msubsup><mml:mrow/><mml:mrow><mml:mn>8</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> T cells, which results in nitric oxide-dependent killing of bacteria by infected macrophages (<xref rid="B51" ref-type="bibr">51</xref>). It has been observed that in Balb/c mice, <italic toggle="yes">Brucella</italic> susceptibility is caused by an increase in the levels of IL-4 and IL-5 produced by Th2 (<xref rid="B50" ref-type="bibr">50</xref>). Among the reviewed articles in this study, IFN-&#947; levels were measured in most studies, which also showed the highest elevation. Other cytokines (e.g., IL-4, IL-5, and IL-17) were less studied or not studied at all.</p><p>The ability of <italic toggle="yes">B. abortus</italic> to produce antigens independent of T-helper cells as well as CTL (cytotoxic T lymphocyte) responses independent of CD<inline-formula><mml:math id="M7" overflow="scroll"><mml:msubsup><mml:mrow/><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> T cells could be used to make vaccines (<xref rid="B50" ref-type="bibr">50</xref>). By conjugating peptides and proteins to <italic toggle="yes">B. abortus</italic>, antibody and CTL responses are evoked in the absence of CD<inline-formula><mml:math id="M8" overflow="scroll"><mml:msubsup><mml:mrow/><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> T cells. This approach has been used successfully in mice and monkeys to produce systemic and neutralizing mucosal antibodies (<xref rid="B50" ref-type="bibr">50</xref>).</p><p>Vaccination helps control brucellosis but does not eradicate it. With 80% vaccination coverage, good results could be achieved (<xref rid="B52" ref-type="bibr">52</xref>). Some additional measures to eradicate <italic toggle="yes">Brucella</italic> are as follows: (1) permanent animal identification and registration system for close monitoring; (2) close monitoring of slaughterhouses, markets, and herds for timely identification of infected animals; (3) continuous monitoring of herd movements to prevent infection and its spread; (4) training veterinarians and supervisors; (5) compensation for farmers' financial losses for the removal of contaminated animals; and (6) legal protection of the consequences of non-compliance with formal preventive measures (<xref rid="B53" ref-type="bibr">53</xref>).</p><p>The future of developing a new brucellosis vaccine depends to some extent on new scientific developments in the field of diagnostic tools. Considering the recent advances in the field of post-genomics, the completion of the human and mouse genome projects provides a golden opportunity to screen genomic responses to <italic toggle="yes">Brucella</italic> infections in the host. In addition, the use of diagnostic systems based on fluorescence or luminescence with the help of a computer can be used to monitor the position of <italic toggle="yes">Brucella in vitro</italic> and <italic toggle="yes">in vivo</italic>. New <italic toggle="yes">Brucella</italic> vaccines should be developed based on a proper understanding of bacterial and host pathogenesis. <italic toggle="yes">Brucella</italic> vaccine research can be accelerated by using signature-tagged transposon mutagenesis (STM), green fluorescent protein (GFP)-expressing <italic toggle="yes">Brucella</italic> strains, and knockout (KO) mice. By using the technique of extensive genome screening, <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> imaging of bacteria and KO mice, the detection of weakened strains is facilitated and the speed of vaccine production is accelerated (<xref rid="B54" ref-type="bibr">54</xref>). In order to produce <italic toggle="yes">Brucella</italic> vaccine, it is necessary to pay attention to the following points: first, to go through the necessary steps to issue a license, second, to evaluate the effectiveness of the vaccine in two animal models (one a small animal, such as a mouse, and the other a larger animal, such as a non-human mammal), and third, determine the safety, immunogenicity, and efficacy of the vaccine. If in some cases it is not possible to check and show the protective efficiency clearly in humans, then the effectiveness should be predicted (<xref rid="B8" ref-type="bibr">8</xref>).</p><p>The limitations of this study are as follows. First of all, the information available in the studies in this systematic review was incomplete in some areas, for example, all the studies that were included in this report did not determine the type of cytokine or the type of immunoglobulin, and this caused the lack of a comprehensive and accurate analysis. Second, different types of vaccines were used in various studies to protect and prevent <italic toggle="yes">Brucella</italic> infection, which led to the dispersal of the contents. It is recommended that other researchers focus on each vaccine separately to obtain a detailed analysis. Third, in this study, only studies that were published in English were included, which may have caused some data to be lost.</p><p>Since <italic toggle="yes">B. melitensis</italic> is the most common <italic toggle="yes">Brucella</italic> species, a live human vaccine based on this bacterium should be developed (<xref rid="B55" ref-type="bibr">55</xref>). Finally, to answer the question of which type of vaccine is the best option for the production of Brucellosis vaccine, one should pay attention to the specific characteristics of each type of vaccine. Although the live attenuated vaccine has good immunogenicity and protective effect, it is difficult to obtain a license for its use. Recombinant vaccines perform very well in human clinical trials and can be a suitable alternative. A subunit vaccine induces immunity, but multiple subunits may be required to produce high protection. Vaccines based on live <italic toggle="yes">Brucella</italic> are expensive because they have to be contaminated at a high level. Vaccines based on purified proteins are not suitable for brucellosis endemic areas because they require a specialist and a refrigerator. Therefore, in such a situation, vector-based vaccines such as DNA vaccines or live attenuated vaccines can be the best option because they enable the transfer of several protective subunits, can be used without injection, are fast and affordable (<xref rid="B8" ref-type="bibr">8</xref>).</p></sec><sec id="s5"><title>Author contributions</title><p>AD, SA, MK, RG, MH, and MT contributed in revising and final approval of the version to be published. All authors agreed and confirmed the manuscript for publication.</p></sec><sec sec-type="COI-statement" id="conf1"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s6"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Valderas</surname><given-names>MW</given-names></name><name name-style="western"><surname>Roop</surname><given-names>RM</given-names></name></person-group>. <source>Brucella and Bioterrorism. Microorganisms and Bioterrorism</source>. <publisher-loc>Springer</publisher-loc> (<year>2006</year>). p. <fpage>139</fpage>&#8211;<lpage>53</lpage>.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yagupsky</surname><given-names>P</given-names></name><name name-style="western"><surname>Baron</surname><given-names>EJ</given-names></name></person-group>. <article-title>Laboratory exposures to brucellae and implications for bioterrorism</article-title>. <source>Emerg Infect Dis.</source> (<year>2005</year>) <volume>11</volume>:<fpage>1180</fpage>. <pub-id pub-id-type="doi">10.3201/eid1108.041197</pub-id><pub-id pub-id-type="pmid">16102304</pub-id><pub-id pub-id-type="pmcid">PMC3320509</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Q</given-names></name></person-group>. <article-title>The advances in brucellosis vaccines</article-title>. <source>Vaccine.</source> (<year>2019</year>) <volume>37</volume>:<fpage>3981</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2019.05.084</pub-id><pub-id pub-id-type="pmid">31176541</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arenas-Gamboa</surname><given-names>A</given-names></name><name name-style="western"><surname>Ficht</surname><given-names>T</given-names></name><name name-style="western"><surname>Kahl-McDonagh</surname><given-names>M</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>G</given-names></name><name name-style="western"><surname>Rice-Ficht</surname><given-names>A</given-names></name></person-group>. <article-title>The <italic toggle="yes">Brucella abortus</italic> S19 &#916; vjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle</article-title>. <source>Infect Immun.</source> (<year>2009</year>) <volume>77</volume>:<fpage>877</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.01017-08</pub-id><pub-id pub-id-type="pmid">19047401</pub-id><pub-id pub-id-type="pmcid">PMC2632017</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Godfroid</surname><given-names>J</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>K</given-names></name><name name-style="western"><surname>Saegerman</surname><given-names>C</given-names></name></person-group>. <article-title>Diagnosis of brucellosis in livestock and wildlife</article-title>. <source>Croat Med J.</source> (<year>2010</year>) <volume>51</volume>:<fpage>296</fpage>&#8211;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.3325/cmj.2010.51.296</pub-id><pub-id pub-id-type="pmid">20718082</pub-id><pub-id pub-id-type="pmcid">PMC2931434</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Godfroid</surname><given-names>J</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>H</given-names></name><name name-style="western"><surname>Barbier</surname><given-names>T</given-names></name><name name-style="western"><surname>Nicolas</surname><given-names>C</given-names></name><name name-style="western"><surname>Wattiau</surname><given-names>P</given-names></name><name name-style="western"><surname>Fretin</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Brucellosis at the animal/ecosystem/human interface at the beginning of the 21st century</article-title>. <source>Prev Vet Med.</source> (<year>2011</year>) <volume>102</volume>:<fpage>118</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.prevetmed.2011.04.007</pub-id><pub-id pub-id-type="pmid">21571380</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicoletti</surname><given-names>P</given-names></name></person-group>. <article-title>Brucellosis: past, present and future</article-title>. <source>Prilozi.</source> (<year>2010</year>) <volume>31</volume>:<fpage>21</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">20703181</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perkins</surname><given-names>SD</given-names></name><name name-style="western"><surname>Smither</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>HS</given-names></name></person-group>. <article-title>Towards a Brucella vaccine for humans</article-title>. <source>FEMS Microbiol Rev.</source> (<year>2010</year>) <volume>34</volume>:<fpage>379</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-6976.2010.00211.x</pub-id><pub-id pub-id-type="pmid">20180858</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name><name name-style="western"><surname>Liberati</surname><given-names>A</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>J</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name></person-group>. <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>Int J Surg.</source> (<year>2010</year>) <volume>8</volume>:<fpage>336</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijsu.2010.02.007</pub-id><pub-id pub-id-type="pmid">20171303</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Institute</surname><given-names>J</given-names></name></person-group>. <source>The Joanna Briggs Institute Critical Appraisal Tools for Use in JBI Systematic Reviews Checklist for Analytical Cross Sectional Studies</source>. <publisher-name>The Joanna Briggs Institute North Adelaide</publisher-name>. (<year>2017</year>).</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curina</surname><given-names>G</given-names></name><name name-style="western"><surname>Nardini</surname><given-names>R</given-names></name><name name-style="western"><surname>Corneli</surname><given-names>S</given-names></name><name name-style="western"><surname>D'Avino</surname><given-names>N</given-names></name><name name-style="western"><surname>Tentellini</surname><given-names>M</given-names></name><name name-style="western"><surname>Montagnoli</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Evaluation of immune responses in mice and sheep inoculated with a live attenuated <italic toggle="yes">Brucella melitensis</italic> REV1 vaccine produced in bioreactor</article-title>. <source>Vet Immunol Immunopathol.</source> (<year>2018</year>) <volume>198</volume>:<fpage>44</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetimm.2018.02.010</pub-id><pub-id pub-id-type="pmid">29571517</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>V</given-names></name><name name-style="western"><surname>Radhakrishnan</surname><given-names>G</given-names></name><name name-style="western"><surname>Harms</surname><given-names>J</given-names></name><name name-style="western"><surname>Splitter</surname><given-names>G</given-names></name></person-group>. <article-title>Invasive <italic toggle="yes">Escherichia coli</italic> vaccines expressing <italic toggle="yes">Brucella melitensis</italic> outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B</article-title>. <source>melitensis Vaccine.</source> (<year>2012</year>) <volume>30</volume>:<fpage>4017</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.036</pub-id><pub-id pub-id-type="pmid">22546330</pub-id><pub-id pub-id-type="pmcid">PMC3361596</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Mariri</surname><given-names>A</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>NH</given-names></name><name name-style="western"><surname>Hammoud</surname><given-names>R</given-names></name></person-group>. <article-title>Efficacy evaluation of live <italic toggle="yes">Escherichia coli</italic> expression Brucella P39 protein combined with CpG oligodeoxynucleotides vaccine against <italic toggle="yes">Brucella melitensis</italic> 16M, in BALB/c mice</article-title>. <source>Biologicals.</source> (<year>2012</year>) <volume>40</volume>:<fpage>140</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.biologicals.2012.01.002</pub-id><pub-id pub-id-type="pmid">22296786</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senevirathne</surname><given-names>A</given-names></name><name name-style="western"><surname>Hewawaduge</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name></person-group>. <article-title>Attenuated Salmonella secreting Brucella protective antigens confer dual-faceted protection against brucellosis and salmonellosis in a mouse model</article-title>. <source>Vet Immunol Immunopathol.</source> (<year>2019</year>) <volume>209</volume>:<fpage>31</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetimm.2019.02.001</pub-id><pub-id pub-id-type="pmid">30885303</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lalsiamthara</surname><given-names>J</given-names></name><name name-style="western"><surname>Won</surname><given-names>G</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name></person-group>. <article-title>Effect of immunization routes and protective efficacy of <italic toggle="yes">Brucella antigens</italic> delivered <italic toggle="yes">via Salmonella vector</italic> vaccine</article-title>. <source>J Vet Sci.</source> (<year>2018</year>) <volume>19</volume>:<fpage>416</fpage>&#8211;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.4142/jvs.2018.19.3.416</pub-id><pub-id pub-id-type="pmid">29366302</pub-id><pub-id pub-id-type="pmcid">PMC5974523</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Surendran</surname><given-names>N</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Lawler</surname><given-names>H</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Hiltbold</surname><given-names>EM</given-names></name><name name-style="western"><surname>Heid</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Efficacy of vaccination strategies against intranasal challenge with <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title>. <source>Vaccine.</source> (<year>2011</year>) <volume>29</volume>:<fpage>2749</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.01.090</pub-id><pub-id pub-id-type="pmid">21316499</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacob</surname><given-names>JM</given-names></name><name name-style="western"><surname>Curtiss</surname><given-names>R</given-names></name> III</person-group>. <article-title>Characterization of <italic toggle="yes">Brucella abortus</italic> S19 as a challenge strain for use in a mouse model of brucellosis</article-title>. <source>Microbes Infection.</source> (<year>2021</year>) <volume>23</volume>:<fpage>104809</fpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2021.104809</pub-id><pub-id pub-id-type="pmid">33753207</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Brucella suis strain 2 vaccine is safe and protective against heterologous <italic toggle="yes">Brucella</italic> spp. infections</article-title>. <source>Vaccine.</source> (<year>2016</year>) <volume>34</volume>:<fpage>395</fpage>&#8211;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.116</pub-id><pub-id pub-id-type="pmid">26626213</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minhas</surname><given-names>P</given-names></name><name name-style="western"><surname>Sunil Kumar</surname><given-names>B</given-names></name><name name-style="western"><surname>Verma</surname><given-names>R</given-names></name></person-group>. <article-title>Evaluation of immuno-modulating effect of recombinant heat shock protein 40 of <italic toggle="yes">Brucella abortus</italic> in mice</article-title>. <source>Biotech.</source> (<year>2019</year>) <volume>9</volume>:<fpage>1</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s13205-019-1905-3</pub-id><pub-id pub-id-type="pmid">31588390</pub-id><pub-id pub-id-type="pmcid">PMC6757077</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain-Gupta</surname><given-names>N</given-names></name><name name-style="western"><surname>Contreras-Rodriguez</surname><given-names>A</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Witonsky</surname><given-names>SG</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name></person-group>. <article-title>Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against <italic toggle="yes">Brucella melitensis</italic> challenge in mice</article-title>. <source>FEMS Immunol Med Microbiol.</source> (<year>2012</year>) <volume>66</volume>:<fpage>436</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1111/1574-695X.12010</pub-id><pub-id pub-id-type="pmid">23163875</pub-id><pub-id pub-id-type="pmcid">PMC4426994</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Gonz&#225;lez</surname><given-names>E</given-names></name><name name-style="western"><surname>Garc&#237;a-Hern&#225;ndez</surname><given-names>AL</given-names></name><name name-style="western"><surname>Flores-Mej&#237;a</surname><given-names>R</given-names></name><name name-style="western"><surname>L&#243;pez-Santiago</surname><given-names>R</given-names></name><name name-style="western"><surname>Moreno-Fierros</surname><given-names>L</given-names></name></person-group>. <article-title>The protoxin Cry1Ac of <italic toggle="yes">Bacillus thuringiensis</italic> improves the protection conferred by intranasal immunization with <italic toggle="yes">Brucella abortus</italic> RB51 in a mouse model</article-title>. <source>Vet Microbiol.</source> (<year>2015</year>) <volume>175</volume>:<fpage>382</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetmic.2014.11.021</pub-id><pub-id pub-id-type="pmid">25497237</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alizadeh</surname><given-names>H</given-names></name><name name-style="western"><surname>Dezfulian</surname><given-names>M</given-names></name><name name-style="western"><surname>Rahnema</surname><given-names>M</given-names></name><name name-style="western"><surname>Fallah</surname><given-names>J</given-names></name><name name-style="western"><surname>Esmaeili</surname><given-names>D</given-names></name></person-group>. <article-title>Protection of BALB/c mice against pathogenic <italic toggle="yes">Brucella abortus</italic> and <italic toggle="yes">Brucella melitensis</italic> by vaccination with recombinant Omp16</article-title>. <source>Iran J Basic Med Sci.</source> (<year>2019</year>) <volume>22</volume>:<fpage>1302</fpage>. <pub-id pub-id-type="doi">10.22038/ijbms.2019.36369.8665</pub-id><pub-id pub-id-type="pmid">32128095</pub-id><pub-id pub-id-type="pmcid">PMC7038423</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansour</surname><given-names>AM</given-names></name></person-group>. <article-title>Effect of levamisole administration on immunogenic and protective capacity of <italic toggle="yes">Brucella abortus</italic> RB51</article-title>. <source>Natl J Physiol Pharm Pharmacol</source>. (<year>2018</year>) <volume>8</volume>:<fpage>635</fpage>. <pub-id pub-id-type="doi">10.5455/njppp.2018.8.1143004122017</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clapp</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Thornburg</surname><given-names>T</given-names></name><name name-style="western"><surname>Walters</surname><given-names>N</given-names></name><name name-style="western"><surname>Pascual</surname><given-names>DW</given-names></name></person-group>. <article-title>Nasal vaccination stimulates CD8+ T cells for potent protection against mucosal <italic toggle="yes">Brucella melitensis</italic> challenge</article-title>. <source>Immunol Cell Biol.</source> (<year>2016</year>) <volume>94</volume>:<fpage>496</fpage>&#8211;<lpage>508</lpage>. <pub-id pub-id-type="doi">10.1038/icb.2016.5</pub-id><pub-id pub-id-type="pmid">26752510</pub-id><pub-id pub-id-type="pmcid">PMC4879022</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arenas-Gamboa</surname><given-names>A</given-names></name><name name-style="western"><surname>Rice-Ficht</surname><given-names>A</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kahl-McDonagh</surname><given-names>M</given-names></name><name name-style="western"><surname>Ficht</surname><given-names>T</given-names></name></person-group>. <article-title>Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16M&#916; vjbR and S19R vjbR in the immunocompromised IRF-1&#8211;/&#8211; mouse model</article-title>. <source>Clin Vaccine Immunol.</source> (<year>2012</year>) <volume>19</volume>:<fpage>249</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.05321-11</pub-id><pub-id pub-id-type="pmid">22169089</pub-id><pub-id pub-id-type="pmcid">PMC3272933</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>L</given-names></name><name name-style="western"><surname>Rawat</surname><given-names>M</given-names></name><name name-style="western"><surname>Prajapati</surname><given-names>A</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>B</given-names></name><name name-style="western"><surname>Chaturvedi</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Protective immune-response of aluminium hydroxide gel adjuvanted phage lysate of <italic toggle="yes">Brucella abortus</italic> S19 in mice against direct virulent challenge with <italic toggle="yes">B. abortus</italic> 544</article-title>. <source>Biologicals.</source> (<year>2015</year>) <volume>43</volume>:<fpage>369</fpage>&#8211;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.biologicals.2015.06.006</pub-id><pub-id pub-id-type="pmid">26156404</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Larson</surname><given-names>CB</given-names></name><name name-style="western"><surname>Ramaker</surname><given-names>MA</given-names></name><name name-style="western"><surname>Quandt</surname><given-names>K</given-names></name><name name-style="western"><surname>Wendte</surname><given-names>JM</given-names></name><name name-style="western"><surname>Ku</surname><given-names>KP</given-names></name><etal/></person-group>. <article-title>Characterization of recombinant <italic toggle="yes">B. abortus</italic> strain RB51SOD toward understanding the uncorrelated innate and adaptive immune responses induced by RB51SOD compared to its parent vaccine strain RB51</article-title>. <source>Front Cell Infect Microbiol.</source> (<year>2011</year>) <volume>1</volume>:<fpage>10</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2011.00010</pub-id><pub-id pub-id-type="pmid">22919576</pub-id><pub-id pub-id-type="pmcid">PMC3417361</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franco</surname><given-names>MP</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>M</given-names></name><name name-style="western"><surname>Gilman</surname><given-names>RH</given-names></name><name name-style="western"><surname>Smits</surname><given-names>HL</given-names></name></person-group>. <article-title>Human brucellosis</article-title>. <source>Lancet Infect Dis.</source> (<year>2007</year>) <volume>7</volume>:<fpage>775</fpage>&#8211;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(07)70286-4</pub-id><pub-id pub-id-type="pmid">18045560</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno</surname><given-names>E</given-names></name></person-group>. <article-title>Retrospective and prospective perspectives on zoonotic brucellosis</article-title>. <source>Front Microbiol.</source> (<year>2014</year>) <volume>5</volume>:<fpage>213</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2014.00213</pub-id><pub-id pub-id-type="pmid">24860561</pub-id><pub-id pub-id-type="pmcid">PMC4026726</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whatmore</surname><given-names>AM</given-names></name></person-group>. <article-title>Current understanding of the genetic diversity of Brucella, an expanding genus of zoonotic pathogens</article-title>. <source>Infect Genet Evol.</source> (<year>2009</year>) <volume>9</volume>:<fpage>1168</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.meegid.2009.07.001</pub-id><pub-id pub-id-type="pmid">19628055</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Luo</surname><given-names>D</given-names></name><name name-style="western"><surname>Xing</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Protection of mice from Brucella infection by immunization with attenuated Salmonella enterica serovar typhimurium expressing A L7/L12 and BLS fusion antigen of Brucella</article-title>. <source>Vaccine.</source> (<year>2009</year>) <volume>27</volume>:<fpage>5214</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.06.075</pub-id><pub-id pub-id-type="pmid">19596411</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquevich</surname><given-names>KA</given-names></name><name name-style="western"><surname>Iba&#241;ez</surname><given-names>AE</given-names></name><name name-style="western"><surname>Coria</surname><given-names>LM</given-names></name><name name-style="western"><surname>Garc&#237;a Samartino</surname><given-names>C</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Zwerdling</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>An oral vaccine based on U-Omp19 induces protection against <italic toggle="yes">B. abortus</italic> mucosal challenge by inducing an adaptive IL-17 immune response in mice</article-title>. <source>PLoS ONE.</source> (<year>2011</year>) <volume>6</volume>:<fpage>e16203</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0016203</pub-id><pub-id pub-id-type="pmid">21264260</pub-id><pub-id pub-id-type="pmcid">PMC3021544</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajasekaran</surname><given-names>P</given-names></name><name name-style="western"><surname>Surendran</surname><given-names>N</given-names></name><name name-style="western"><surname>Seleem</surname><given-names>MN</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name></person-group>. <article-title>Over-expression of homologous antigens in a leucine auxotroph of <italic toggle="yes">Brucella abortus</italic> strain RB51 protects mice against a virulent <italic toggle="yes">B. suis</italic> challenge</article-title>. <source>Vaccine.</source> (<year>2011</year>) <volume>29</volume>:<fpage>3106</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.02.054</pub-id><pub-id pub-id-type="pmid">21376799</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ingolotti</surname><given-names>M</given-names></name><name name-style="western"><surname>Kawalekar</surname><given-names>O</given-names></name><name name-style="western"><surname>Shedlock</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Muthumani</surname><given-names>K</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>DB</given-names></name> DNA</person-group>. <article-title>vaccines for targeting bacterial infections</article-title>. <source>Expert Rev Vaccines.</source> (<year>2010</year>) <volume>9</volume>:<fpage>747</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1586/erv.10.57</pub-id><pub-id pub-id-type="pmid">20624048</pub-id><pub-id pub-id-type="pmcid">PMC2962930</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garry Adams</surname><given-names>L</given-names></name><name name-style="western"><surname>J Schutta</surname><given-names>C</given-names></name></person-group>. <article-title>Natural resistance against brucellosis: a review</article-title>. <source>Open Vet Sci J</source>. (<year>2010</year>) <volume>4</volume>:<fpage>61</fpage>. <pub-id pub-id-type="doi">10.2174/1874318801004010061</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herrera-L&#243;pez</surname><given-names>E</given-names></name><name name-style="western"><surname>Su&#225;rez-G&#252;emes</surname><given-names>F</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Andrade</surname><given-names>L</given-names></name><name name-style="western"><surname>C&#243;rdova-L&#243;pez</surname><given-names>D</given-names></name><name name-style="western"><surname>D&#237;az-Aparicio</surname><given-names>E</given-names></name></person-group>. <article-title>Epidemiological study of Brucellosis in cattle, immunized with <italic toggle="yes">Brucella abortus</italic> RB51 vaccine in endemic zones</article-title>. <source>Vaccine.</source> (<year>2010</year>) <volume>28</volume>(<issue>Suppl. 5</issue>):<fpage>F59</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.03.057</pub-id><pub-id pub-id-type="pmid">20362623</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Skyberg</surname><given-names>JA</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name><name name-style="western"><surname>Clapp</surname><given-names>B</given-names></name><name name-style="western"><surname>Thornburg</surname><given-names>T</given-names></name><name name-style="western"><surname>Pascual</surname><given-names>DW</given-names></name></person-group>. <article-title>Progress in Brucella vaccine development</article-title>. <source>Front Biol.</source> (<year>2013</year>) <volume>8</volume>:<fpage>60</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1007/s11515-012-1196-0</pub-id><pub-id pub-id-type="pmid">23730309</pub-id><pub-id pub-id-type="pmcid">PMC3666581</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Corbel</surname><given-names>MJ</given-names></name></person-group>. <article-title>Brucellosis vaccines: past, present and future</article-title>. <source>Vet Microbiol.</source> (<year>2002</year>) <volume>90</volume>:<fpage>479</fpage>&#8211;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-1135(02)00255-9</pub-id><pub-id pub-id-type="pmid">12414166</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gheibi</surname><given-names>A</given-names></name><name name-style="western"><surname>Khanahmad</surname><given-names>H</given-names></name><name name-style="western"><surname>Kashfi</surname><given-names>K</given-names></name><name name-style="western"><surname>Sarmadi</surname><given-names>M</given-names></name><name name-style="western"><surname>Khorramizadeh</surname><given-names>MR</given-names></name></person-group>. <article-title>Development of new generation of vaccines for <italic toggle="yes">Brucella abortus</italic></article-title>. <source>Heliyon</source>. (<year>2018</year>) <volume>4</volume>:<fpage>e01079</fpage>. <pub-id pub-id-type="doi">10.1016/j.heliyon.2018.e01079</pub-id><pub-id pub-id-type="pmid">30603712</pub-id><pub-id pub-id-type="pmcid">PMC6307385</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sislema-Egas</surname><given-names>F</given-names></name><name name-style="western"><surname>C&#233;spedes</surname><given-names>S</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>P</given-names></name><name name-style="western"><surname>Retamal-D&#237;az</surname><given-names>A</given-names></name><name name-style="western"><surname>S&#225;ez</surname><given-names>D</given-names></name><name name-style="western"><surname>O&#241;ate</surname><given-names>A</given-names></name></person-group>. <article-title>Evaluation of protective effect of DNA vaccines encoding the BAB1_0263 and BAB1_0278 open reading frames of <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title>. <source>Vaccine.</source> (<year>2012</year>) <volume>30</volume>:<fpage>7286</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.039</pub-id><pub-id pub-id-type="pmid">23026687</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez</surname><given-names>L</given-names></name><name name-style="western"><surname>Llanos</surname><given-names>J</given-names></name><name name-style="western"><surname>Escalona</surname><given-names>E</given-names></name><name name-style="western"><surname>Saez</surname><given-names>D</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>F</given-names></name><name name-style="western"><surname>Molina</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Multivalent Fusion DNA Vaccine against <italic toggle="yes">Brucella abortus</italic></article-title>. <source>Biomed Res Int</source>. (<year>2017</year>) <volume>2017</volume>:<fpage>6535479</fpage>. <pub-id pub-id-type="doi">10.1155/2017/6535479</pub-id><pub-id pub-id-type="pmid">29082252</pub-id><pub-id pub-id-type="pmcid">PMC5610864</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurunathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C-Y</given-names></name><name name-style="western"><surname>Freidag</surname><given-names>BL</given-names></name><name name-style="western"><surname>Seder</surname><given-names>RA</given-names></name> DNA</person-group>. <article-title>vaccines: a key for inducing long-term cellular immunity</article-title>. <source>Curr Opin Immunol.</source> (<year>2000</year>) <volume>12</volume>:<fpage>442</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S0952-7915(00)00118-7</pub-id><pub-id pub-id-type="pmid">10899026</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayraklioglu</surname><given-names>N</given-names></name><name name-style="western"><surname>Horuluoglu</surname><given-names>B</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>DM</given-names></name></person-group>. <article-title>CpG oligonucleotides as vaccine adjuvants</article-title>. <source>DNA Vaccines</source>. (<year>2021</year>) <volume>21967</volume>:<fpage>51</fpage>&#8211;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-0716-0872-2_4</pub-id><pub-id pub-id-type="pmid">32827132</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>K</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>C</given-names></name></person-group>. <article-title>A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases</article-title>. <source>Drugs R D.</source> (<year>2008</year>) <volume>9</volume>:<fpage>137</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.2165/00126839-200809030-00001</pub-id><pub-id pub-id-type="pmid">18457466</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klinman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Klaschik</surname><given-names>S</given-names></name><name name-style="western"><surname>Sato</surname><given-names>T</given-names></name><name name-style="western"><surname>Tross</surname><given-names>D</given-names></name></person-group>. <article-title>CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases</article-title>. <source>Adv Drug Deliv Rev.</source> (<year>2009</year>) <volume>61</volume>:<fpage>248</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2008.12.012</pub-id><pub-id pub-id-type="pmid">19272313</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abadi</surname><given-names>AH</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M</given-names></name><name name-style="western"><surname>Khaledi</surname><given-names>A</given-names></name><name name-style="western"><surname>Esmaeili</surname><given-names>S-A</given-names></name><name name-style="western"><surname>Esmaeili</surname><given-names>D</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A</given-names></name></person-group>. <article-title>Study of serum bactericidal and splenic activity of Total-OMP-CagA combination from <italic toggle="yes">Brucella abortus</italic> and <italic toggle="yes">Helicobacter pylori</italic> in BALB/c mouse model</article-title>. <source>Microb Pathog.</source> (<year>2018</year>) <volume>121</volume>:<fpage>100</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2018.04.050</pub-id><pub-id pub-id-type="pmid">29709690</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iannino</surname><given-names>F</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>CK</given-names></name><name name-style="western"><surname>Roset</surname><given-names>MS</given-names></name><name name-style="western"><surname>Briones</surname><given-names>G</given-names></name></person-group>. <article-title>Development of a dual vaccine for prevention of <italic toggle="yes">Brucella abortus</italic> infection and <italic toggle="yes">Escherichia coli</italic> O157: H7 intestinal colonization</article-title>. <source>Vaccine.</source> (<year>2015</year>) <volume>33</volume>:<fpage>2248</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.03.033</pub-id><pub-id pub-id-type="pmid">25820069</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrero</surname><given-names>MC</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>IMA</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>FM</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>PC</given-names></name></person-group>. <article-title>Pathogenesis and immune response in Brucella infection acquired by the respiratory route</article-title>. <source>Microbes Infect.</source> (<year>2020</year>) <volume>22</volume>:<fpage>407</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2020.06.001</pub-id><pub-id pub-id-type="pmid">32535086</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smither</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>SD</given-names></name><name name-style="western"><surname>Davies</surname><given-names>C</given-names></name><name name-style="western"><surname>Stagg</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>M</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>HS</given-names></name></person-group>. <article-title>Development and characterization of mouse models of infection with aerosolized <italic toggle="yes">Brucella melitensis</italic> and <italic toggle="yes">Brucella suis</italic></article-title>. <source>Clin Vaccine Immunol</source>. (<year>2009</year>) <volume>16</volume>:<fpage>779</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00029-09</pub-id><pub-id pub-id-type="pmid">19321692</pub-id><pub-id pub-id-type="pmcid">PMC2681579</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golding</surname><given-names>B</given-names></name><name name-style="western"><surname>Scott</surname><given-names>DE</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>O</given-names></name><name name-style="western"><surname>Huang</surname><given-names>LY</given-names></name><name name-style="western"><surname>Zaitseva</surname><given-names>M</given-names></name><name name-style="western"><surname>Lapham</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Immunity and protection against <italic toggle="yes">Brucella abortus</italic></article-title>. <source>Microbes Infect</source>. (<year>2001</year>) <volume>3</volume>:<fpage>43</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S1286-4579(00)01350-2</pub-id><pub-id pub-id-type="pmid">11226853</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boschiroli</surname><given-names>ML</given-names></name><name name-style="western"><surname>Foulongne</surname><given-names>V</given-names></name><name name-style="western"><surname>O'Callaghan</surname><given-names>D</given-names></name></person-group>. <article-title>Brucellosis: a worldwide zoonosis</article-title>. <source>Curr Opin Microbiol.</source> (<year>2001</year>) <volume>4</volume>:<fpage>58</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/S1369-5274(00)00165-X</pub-id><pub-id pub-id-type="pmid">11173035</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Animal brucellosis control or eradication programs worldwide: a systematic review of experiences and lessons learned</article-title>. <source>Prev Vet Med.</source> (<year>2018</year>) <volume>160</volume>:<fpage>105</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.prevetmed.2018.10.002</pub-id><pub-id pub-id-type="pmid">30388992</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zamri-Saad</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamarudin</surname><given-names>M</given-names></name></person-group>. <article-title>Control of animal brucellosis: the Malaysian experience</article-title>. <source>Asian Pac J Trop Med.</source> (<year>2016</year>) <volume>9</volume>:<fpage>1136</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.apjtm.2016.11.007</pub-id><pub-id pub-id-type="pmid">27955740</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>J</given-names></name><name name-style="western"><surname>Splitter</surname><given-names>GA</given-names></name></person-group>. <article-title>Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans</article-title>. <source>Clin Microbiol Rev.</source> (<year>2003</year>) <volume>16</volume>:<fpage>65</fpage>&#8211;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.16.1.65-78.2003</pub-id><pub-id pub-id-type="pmid">12525425</pub-id><pub-id pub-id-type="pmcid">PMC145300</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clapp</surname><given-names>B</given-names></name><name name-style="western"><surname>Skyberg</surname><given-names>JA</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Thornburg</surname><given-names>T</given-names></name><name name-style="western"><surname>Walters</surname><given-names>N</given-names></name><name name-style="western"><surname>Pascual</surname><given-names>DW</given-names></name></person-group>. <article-title>Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses</article-title>. <source>Infect Immun.</source> (<year>2011</year>) <volume>79</volume>:<fpage>4165</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.05080-11</pub-id><pub-id pub-id-type="pmid">21768283</pub-id><pub-id pub-id-type="pmcid">PMC3187253</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>